A5052203408- Hematopoietic Stem Cell Transplantation
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Acute Myeloid Leukemia Research
- Multiple Myeloma Research and Treatments
- Chronic Myeloid Leukemia Treatments
- Renal Transplantation Outcomes and Treatments
- Immune Cell Function and Interaction
- Antifungal resistance and susceptibility
- Fungal Infections and Studies
- Cytomegalovirus and herpesvirus research
- Neutropenia and Cancer Infections
- Polyomavirus and related diseases
- CAR-T cell therapy research
- T-cell and B-cell Immunology
- Immunodeficiency and Autoimmune Disorders
- Viral-associated cancers and disorders
- Cancer Treatment and Pharmacology
- Retinoids in leukemia and cellular processes
- Immunotherapy and Immune Responses
- Pneumocystis jirovecii pneumonia detection and treatment
- Childhood Cancer Survivors' Quality of Life
- Protein Degradation and Inhibitors
- Myeloproliferative Neoplasms: Diagnosis and Treatment
Emory University
2016-2025
Winship Cancer Institute
2013-2024
American Heart Association
2024
University of Minnesota
2023
Leipzig University
2023
Emory University Hospital
2004-2020
Piedmont Cancer Institute
2010-2020
Astellas Pharma (United Kingdom)
2019
Chimerix (United States)
2019
Incyte (United States)
2019
Invasive fungal infections are an important cause of morbidity and mortality after allogeneic hematopoietic stem-cell transplantation.
Background. Invasive aspergillosis is an important cause of morbidity and mortality in immunocompromised patients. Current treatments provide limited benefit. Posaconazole extended-spectrum triazole with vitro vivo activity against Aspergillus species.
ABSTRACT Zygomycosis, an infection that is associated with significant morbidity and mortality, becoming common in immunocompromised patients. Posaconazole a new extended-spectrum azole antifungal has demonstrated vitro vivo activity against zygomycetes. This report provides the results from first 24 patients active zygomycosis who were enrolled two open-label, nonrandomized, multicentered compassionate trials evaluated oral posaconazole as salvage therapy for invasive fungal infections. was...
To provide guidelines on antimicrobial prophylaxis for adult neutropenic oncology outpatients and selection treatment as of those with fever neutropenia.A literature search identified relevant studies published in English. Primary outcomes included: development and/or infections afebrile recovery without complications overall mortality febrile outpatients. Secondary outpatients, infection-related mortality; neutropenia, defervescence regimen change, time to defervescence, infectious...
<h3>Context</h3>A minimally toxic nonmyeloablative regimen was developed for allogeneic hematopoietic cell transplantation (HCT) to treat patients with advanced hematologic malignancies who are older or have comorbid conditions.<h3>Objective</h3>To describe outcomes of 60 years after receiving HCT.<h3>Design, Setting, and Participants</h3>From 1998 2008, 372 aged 75 were enrolled in prospective clinical HCT trials at 18 collaborating institutions using conditioning low-dose total body...
Purpose We reported encouraging early results of allogeneic hematopoietic cell transplantation (HCT) after nonmyeloablative conditioning in 64 patients who had advanced chronic lymphocytic leukemia (CLL). Here, we have extended the follow-up to a median 5 years and included data on an additional 18 patients. Patients Methods Eighty-two patients, age 42 72 years, fludarabine-refractory CLL were conditioned with 2 Gy total-body irradiation alone or combined fludarabine followed by HCT from...
BackgroundCytomegalovirus reactivation occurs within 6 months in 60–70% of cytomegalovirus-seropositive patients after allogeneic haemopoietic stem-cell transplantation (HSCT), mainly due to immunosuppression associated with the procedure. Pre-emptive antiviral therapy reduces incidence cytomegalovirus disease but can be toxic. To reduce potential for and subsequent need such drugs, we aimed assess safety efficacy a therapeutic DNA vaccine compared placebo.MethodsIn this exploratory...
We designed a minimal-intensity conditioning regimen for allogeneic hematopoietic cell transplantation (HCT) in patients with advanced hematologic malignancies unable to tolerate high-intensity regimens because of age, serious comorbidities, or previous high-dose HCT. The allows the purest assessment graft-versus-tumor (GVT) effects apart from and graft-versus-host disease (GVHD) not augmented by regimen-related toxicities.Patients received low-dose total-body irradiation ± fludarabine...
Cytomegalovirus (CMV) infections that are refractory or resistant (RR) to available antivirals ([val]ganciclovir, foscarnet, cidofovir) associated with higher mortality in transplant patients. Maribavir is active against RR CMV strains.Hematopoietic-cell solid-organ recipients ≥12 years old and plasma deoxyribonucleic acid (DNA) ≥1000 copies/mL were randomized (1:1:1) twice-daily dose-blinded maribavir 400, 800, 1200 mg for up 24 weeks. The primary efficacy endpoint was the proportion of...
Severe (grade 3-4) acute graft-versus-host disease (AGVHD) is a major cause of death after unrelated-donor (URD) hematopoietic cell transplant (HCT), resulting in particularly high mortality HLA-mismatched transplantation. There are no approved agents for AGVHD prevention, underscoring the critical unmet need novel therapeutics. ABA2 was phase II trial to rigorously assess safety, efficacy, and immunologic effects adding T-cell costimulation blockade with abatacept calcineurin inhibitor...
Inherited mutations in the BRCA1 gene are associated with a high risk of breast and ovarian cancer some families. However, little is known about contribution to general population. We analyzed DNA samples from women enrolled population-based study early-onset assess spectrum frequency germ-line young cancer.
BACKGROUND Elderly and medically infirm cancer patients are increasingly offered allogeneic nonmyeloablative hematopoietic cell transplantation (HCT). A better understanding of the impact health status on HCT outcomes is warranted. Herein, a recently developed HCT-specific comorbidity index (HCT-CI) was compared with widely acceptable measure status, Karnofsky performance (KPS). METHODS The 341 were evaluated, conditioned for either related or unrelated by 2-gray (Gy) total body irradiation...
Patients with chemotherapy-refractory chronic lymphocytic leukemia (CLL) have a short life expectancy. The aim of this study was to analyze the outcome patients advanced CLL when treated nonmyeloablative conditioning and hematopoietic cell transplantation (HCT).Sixty-four diagnosed were (2 Gy total-body irradiation [n = 53] or without 11] fludarabine) HCT from related (n 44) unrelated 20) donors. An adapted form Charlson comorbidity index used assess pretransplantation...
A genetic linkage map of the canine genome has been developed by typing 150 microsatellite markers using 17 three-generation pedigrees, composed 163 F2individuals. One hundred and thirty-nine were linked to at least one other marker with a lod score ≥ 3.0, identifying 30 groups. The largest chromosome had 9 spanning 106.1 cM. average distance between was 14.03 cM, covers an estimated 2073 Eleven informative on mapping panel, but unlinked any marker. These likely represent single located...
Invasive fungal infections are found most frequently in immunosuppressed and critically ill hospitalized patients. Antifungal therapy is often required for long periods. Safety data from the clinical development program of triazole antifungal agent, posaconazole, were analyzed.A total 428 patients with refractory invasive (n = 362) or febrile neutropenia 66) received posaconazole 2 phase II/III open-label trials. Also, 109 these > 6 months. Incidences treatment-emergent, treatment-related,...
Allogeneic hematopoietic cell transplantation (HCT) after high-dose conditioning regimens imposes prohibitively high risks of morbidity and mortality for patients with high-risk acute myeloid leukemia (AML) who are older or have comorbid conditions. Here, we examined outcomes nonmyeloablative allogeneic HCT in such patients.Two hundred seventy-four (median age, 60 years) de novo secondary AML underwent from related (n = 118) unrelated donors 156) 2 Gy total-body irradiation (TBI) without...
During the early 1970s, attention was called to changing demographics and poor prognosis of patients with miliary tuberculosis. Thirty-eight non-AIDS tuberculosis seen since 1975 are reviewed. Their average age 60 years. Two-thirds had comorbid conditions. Presenting symptoms were nonspecific; fever, anorexia, sweats, weight loss most frequent. Fever, tachypnea, rales, altered mental status commonly associated signs. Chest radiographs often showed disease, but remainder laboratory...
Few effective treatment options exist for chemotherapy-refractory indolent or transformed non-Hodgkin's lymphoma (NHL). We examined the outcome of nonmyeloablative allogeneic hematopoietic cell transplantation (HCT) in this setting.Sixty-two patients with NHL were treated HCT from related (n = 34) unrelated 28) donors after conditioning 2 Gy total-body irradiation without fludarabine. Nine mismatched >/= one HLA antigen. Sixteen had histologic transformation before HCT. Twenty (32%)...